Charles Explorer logo
🇬🇧

Stem cell transplantation in children with myelodysplastic syndrome in the Czech Republic 1997-2002

Publication at Second Faculty of Medicine |
2003

Abstract

Myelodysplastic syndrome (MDS) is a rare, clonal abnormality of the pluripotent haematopoietic stem cell. Stem cell transplantation (SCT) is the only curative treatment modality which has been for a long time connected with high transplant related mortality and relapse.

The Czech Republic participates in the international study EWOG-MDS. In this study children are indicated to SCT early using a very intensive myeloablative conditioning regimen comprising 3 alkylating agents - busulfan, cyclophosphamide and melphalan.

Between 1997-2002, 14 children with primary MDS (JMML: 5, RC: 4, RAEB: 2, RAEBt: 2, MDSr-AML: 1) were transplanted from HLA identical siblings (n = 7) or unrelated donors (n = 7). Median age at the SCT was 5.8 years; median time from diagnosis to SCT was 5 months.

A conditioning regimen of 3 alkylating agents was used in 12 children; two patients with refractory cytopenia were transplanted from unrelated donors using a non-myeloablative conditioning regimen of fludarabin and thiotepa. As GVHD prophylaxis cyclosporin was used alone (n = 5) or in combination with methotrexate (n = 7) or steroids (n = 1).

All patients engrafted. Acute GVHD grades II-IV developed in 57 % patients and extensive chronic GVHD in 20 % children.

Four children (28.5 %) died due to transplant related causes and one patient (7 %) after syngeneic SCT developed a relapse treated by a second SCT from an unrelated donor. After a median follow-up of 1.9 years, 10 children (71 %) are alive in complete remission.

Allogeneic SCT performed according to the EWOG-MDS recommendations improved significantly the prognosis of children with MDS in the Czech Republic.